fbpx

NEW DATA FROM OXFORD UNIVERSITY HOSPITALS DEMONSTRATE SUPERIOR OUTCOME WITH CERAMENTT ANTIBIOTIC ELUTING BONE SUBSTITUTE COMPARED TO COLLAGEN AND CALCIUM SULFATE IN THE MANAGEMENT OF CHRONIC OSTEOMYELITIS

These study results further support the potential benefit of CERAMENTT’G in the management of chronic osteomyelitis,” said Martin McNally, Lead Surgeon of the Bone Infection Unit at the Nuffield Orthopaedic Centre in Oxford, UK and President-Elect of EBJIS.  “We believe the high level of antibiotics combined with a highly controlled release profile as well as the consistent bone remodeling contributed to the superior performance of CERAMENTT’G.”

CERAMENTT’G is the first antibiotic eluting bone substitute indicated to promote and protect bone healing in the management of osteomyelitis.

 “We are extremely pleased with the performance of CERAMENTT’G in this study,” said Lloyd Diamond, CEO of BONESUPPORTT.  “Not only did CERAMENTT’G outperform in all outcome measures, it did so with a higher percentage of highly compromised patients which is most impressive.”

About BONESUPPORTT

BONESUPPORTT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G and CERAMENTT’V are not available in the United States.

CERAMENTT is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENTT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENTT spans more than eleven years. Over fifty pre-clinical, clinical and animal studies have been conducted and more than 20,000 patients have been treated with CERAMENTT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORTT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
Offer.Nonhoff@bonesupport.com
Phone +46 46 286 53 60
PR 0450-01 en

News

Danish researchers provide proof: Caesarean sections can lead to asthma and allergies
12. November 2020
Brand-new medical treatment for cocaine addiction
10. November 2020
90 million to 18 Talented Researchers
19. October 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge